Treatment

EXT-19477 clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedPhase I and Phase II (Integrated)- First administration to humans
PHASE 1/2 STUDY OF PARG INHIBITOR ETX-19477 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
This study is testing a new medicine, ETX-19477, for advanced cancers that haven't responded to usual treatments. It aims to see if the medicine is safe, what dose works best, and if it can shrink tumours or stop them from growing. It's an early-stage study.
For: Patients with advanced solid malignancies that have progressed following standard therapy
Spain · France · Italy